Publications
Detailed Information
Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young-Sil | - |
dc.contributor.author | Youn, HyunChul | - |
dc.contributor.author | Jeong, Hyun-Ghang | - |
dc.contributor.author | Lee, Tae-Jin | - |
dc.contributor.author | Han, Ji Won | - |
dc.contributor.author | Park, Joon Hyuk | - |
dc.contributor.author | Kim, Ki Woong | - |
dc.date.accessioned | 2021-08-30T00:01:38Z | - |
dc.date.available | 2021-08-30T09:04:09Z | - |
dc.date.issued | 2021-08-14 | - |
dc.identifier.citation | Cost Effectiveness and Resource Allocation. 2021 Aug 14;19(1):50 | ko_KR |
dc.identifier.issn | 1478-7547 | - |
dc.identifier.uri | https://hdl.handle.net/10371/174843 | - |
dc.description.abstract | Background
Amyloid positron emission tomography (PET) makes it possible to diagnose Alzheimers disease (AD) in its prodromal phase including mild cognitive impairment (MCI). This study evaluated the cost-effectiveness of including amyloid-PET for assessing individuals with MCI. Methods The target population was 60-year-old patients who were diagnosed with MCI. We constructed a Markov model for the natural history of AD with the amyloid positivity (AP). Because amyloid-PET can detect the AP MCI state, AD detection can be made faster by reducing the follow-up interval for a high-risk group. The health outcomes were evaluated in quality-adjusted life years (QALYs) and the final results of cost-effectiveness analysis were presented in the form of the Incremental Cost-Effectiveness Ratio (ICER). To handle parameter uncertainties, one-way sensitivity analyses for various variables were performed. Results Our model showed that amyloid-PET increased QALYs by 0.003 in individuals with MCI. The estimated additional costs for adopting amyloid-PET amounted to a total of 1250 USD per patient when compared with the cost when amyloid-PET is not adopted. The ICER was 3,71,545 USD per QALY. According to the sensitivity analyses, treatment effect of Donepezil and virtual intervention effect in MCI state were the most influential factors. Conclusions In our model, using amyloid-PET at the MCI stage was not cost-effective. Future advances in management of cognitive impairment would enhance QALYs, and consequently improve cost-effectiveness. | ko_KR |
dc.description.sponsorship | This project was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HC15C1509 to JW Han, JH Park, TJ Lee, and HG Jeong). Additional funding came from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea
[HI09C1379 (A092077) to KW Kim]. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.subject | Alzheimer’s disease | - |
dc.subject | Amyloid | - |
dc.subject | Mild cognitive impairment | - |
dc.subject | Cost-efectiveness | - |
dc.subject | Early diagnosis | - |
dc.title | Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이영실 | - |
dc.contributor.AlternativeAuthor | 윤현철 | - |
dc.contributor.AlternativeAuthor | 정현강 | - |
dc.contributor.AlternativeAuthor | 이태진 | - |
dc.contributor.AlternativeAuthor | 한지원 | - |
dc.contributor.AlternativeAuthor | 박준혁 | - |
dc.contributor.AlternativeAuthor | 김기웅 | - |
dc.identifier.doi | 10.1186/s12962-021-00300-9 | - |
dc.citation.journaltitle | Cost Effectiveness and Resource Allocation | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2021-08-15T03:34:40Z | - |
dc.citation.number | 1 | ko_KR |
dc.citation.startpage | 50 | ko_KR |
dc.citation.volume | 19 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.